Stay updated on Pembrolizumab Combo in Endometrial Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Combo in Endometrial Cancer Clinical Trial page.

Latest updates to the Pembrolizumab Combo in Endometrial Cancer Clinical Trial page
- Check4 days agoChange DetectedThe web page has been updated to indicate that the ClinicalTrials.gov data ingest will be modernized in June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.SummaryDifference6%
- Check11 days agoNo Change Detected
- Check18 days agoNo Change Detected
- Check32 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.3%
- Check47 days agoChange DetectedThe web page has been updated to version 2.15.0 from version 2.14.4, indicating a revision in the content. The phrase 'Here’s how you know' has been modified, suggesting a change in the way information is presented.SummaryDifference0.9%
- Check54 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4, and a date has been added for February 17, 2025. However, the changes do not significantly impact core content or important information.SummaryDifference0.9%
- Check90 days agoChange DetectedThe page has added a date of 2025-02-17, while a previous date of 2025-01-13 has been removed. Additionally, a notice regarding heavy traffic affecting NLM-NCBI services has been deleted.SummaryDifference6%
- Check111 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference5%
Stay in the know with updates to Pembrolizumab Combo in Endometrial Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo in Endometrial Cancer Clinical Trial page.